• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications do not work for many people who are depressed. Personalized treatment could be the solution.

Cue is a digital intervention platform that translates passively acquired normal sensor data from smartphones into customized micro-interventions to improve mental health. We looked at the best-fitting personal ML models to each person using Shapley values to discover their characteristic predictors. The results revealed distinct characteristics that were deterministically changing mood over time.

Predictors of Mood

recurrent depression treatment is the leading cause of mental illness in the world.1 Yet the majority of people suffering from the condition receive treatment. To improve the outcomes, doctors must be able to recognize and treat patients who have the highest probability of responding to certain treatments.

A customized depression anxiety treatment near me treatment plan can aid. Using sensors on mobile phones as well as an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. Two grants worth more than $10 million will be used to discover biological and behavior predictors of response.

The majority of research into predictors of depression treatment effectiveness has centered on the sociodemographic and clinical aspects. These include demographic variables such as age, gender and educational level, clinical characteristics like symptoms severity and comorbidities and biological markers like neuroimaging and genetic variation.

While many of these aspects can be predicted from the data in medical records, few studies have employed longitudinal data to explore the causes of mood among individuals. Few studies also take into consideration the fact that moods can differ significantly between individuals. Therefore, it is crucial to develop methods that permit the recognition of different mood predictors for each person and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can detect various patterns of behavior and emotions that differ between individuals.

The team also created a machine learning algorithm to identify dynamic predictors of each person's mood for depression. The algorithm blends the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, a psychometrically validated symptom severity scale. However, the correlation was weak (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is a leading cause of disability around the world1, but it is often untreated and misdiagnosed. In addition the absence of effective treatments and stigmatization associated with depression treatment psychology disorders hinder many from seeking treatment.

To help with personalized treatment, it is essential to determine the predictors of symptoms. However, current prediction methods depend on the clinical interview which is not reliable and only detects a tiny number of symptoms that are associated with depression.2

Machine learning can increase the accuracy of diagnosis and treatment for depression by combining continuous digital behavior phenotypes collected from smartphone sensors with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can provide continuous, high-resolution measurements as well as capture a wide variety of distinctive behaviors and activity patterns that are difficult to capture with interviews.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA menopause depression treatment Grand Challenge. Participants were directed to online assistance or medical care according to the degree of their depression. Participants who scored a high on the CAT DI of 35 or 65 students were assigned online support with a coach and those with a score 75 patients were referred to in-person clinical care for psychotherapy.

At the beginning, participants answered an array of questions regarding their personal demographics and psychosocial characteristics. These included sex, age and education, as well as work and financial situation; whether they were divorced, married or single; their current suicidal ideas, intent or attempts; as well as the frequency with which they drank alcohol. Participants also rated their level of depression symptom severity on a scale ranging from 0-100 using the CAT-DI. CAT-DI assessments were conducted each week for those that received online support, and once a week for those receiving in-person support.

Predictors of the Reaction to Treatment

Research is focusing on personalization of depression treatment. Many studies are focused on identifying predictors, which will help clinicians identify the most effective drugs for each person. Particularly, pharmacogenetics is able to identify genetic variants that determine how the body metabolizes antidepressants. This allows doctors select medications that are most likely to work for each patient, while minimizing the time and effort needed for trial-and error treatments and avoiding any side negative effects.

Another approach that is promising is to build models of prediction using a variety of data sources, combining data from clinical studies and neural imaging data. These models can then be used to determine the most effective combination of variables that is predictors of a specific outcome, such as whether or not a drug will improve the mood and symptoms. These models can be used to predict the response of a patient to a treatment, allowing doctors maximize the effectiveness.

A new generation employs machine learning methods such as the supervised and classification algorithms, regularized logistic regression and tree-based techniques to combine the effects of several variables and improve predictive accuracy. These models have been proven to be effective in forecasting treatment outcomes, such as the response to antidepressants. These approaches are becoming more popular in psychiatry and could become the standard of future medical practice.

In addition to the ML-based prediction models The study of the mechanisms behind depression continues. Recent research suggests that the disorder is linked with neural dysfunctions that affect specific circuits. This suggests that an individualized treatment for depression will be based upon targeted therapies that restore normal function alternative ways to treat depression these circuits.

Internet-based-based therapies can be an effective method to accomplish this. They can offer more customized and personalized experience for patients. One study found that a web-based program was more effective than standard treatment in alleviating symptoms and ensuring the best quality of life for patients suffering from MDD. Furthermore, a randomized controlled study of a customized treatment for depression demonstrated an improvement in symptoms and fewer side effects in a significant proportion of participants.

Predictors of adverse effects

In the treatment of depression, a major challenge is predicting and determining the antidepressant that will cause no or minimal side negative effects. Many patients are prescribed various medications before settling on a treatment that is effective and tolerated. Pharmacogenetics is an exciting new way to take an effective and precise approach to selecting antidepressant treatments.

There are several variables that can be used to determine the antidepressant to be prescribed, including gene variations, phenotypes of patients like gender or ethnicity and the presence of comorbidities. To determine the most reliable and accurate predictors for a particular treatment, controlled trials that are randomized with larger sample sizes will be required. This is because the detection of moderators or interaction effects can be a lot more difficult in trials that consider a single episode of treatment per patient, rather than multiple episodes of treatment over a period of time.

In addition to that, predicting a patient's reaction will likely require information on the comorbidities, symptoms profiles and the patient's personal experience of tolerability and effectiveness. Presently, only a handful of easily measurable sociodemographic and clinical variables seem to be reliably associated with the severity of MDD like gender, age race/ethnicity, BMI and the presence of alexithymia, and the severity of depressive symptoms.

The application of pharmacogenetics in depression treatment is still in its infancy and there are many obstacles to overcome. First is a thorough understanding of the genetic mechanisms is essential, as is an understanding of what is a reliable predictor of treatment response. Ethics like privacy, and the ethical use of genetic information must also be considered. In the long run pharmacogenetics can offer a chance to lessen the stigma associated with mental health treatment and improve the treatment outcomes for patients with depression. Like any other psychiatric treatment it is crucial to take your time and carefully implement the plan. The best option is to offer patients a variety of effective depression medication options and encourage them to speak with their physicians about their concerns and experiences.